Samuel Bjork

Samuel is a Partner at Digitalis Ventures.

He serves as a director on the boards of Bonum Therapeutics, Elemental Machines, EpiBiologics, Judo Bio, T-Therapeutics, and Terray Therapeutics. He has also served as a board director of PetMedix (acquired by Zoetis) and board observer of Good Therapeutics (acquired by Roche), ScoutBio (acquired by Ceva), SeQure Dx (acquired by MaxCyte), Nuvig Therapeutics, and Switch Therapeutics.

Prior to Digitalis, Samuel was a member of the healthcare and clean energy practices at the Boston Consulting Group. He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University.